Regeneron Reports the EUA Expansion for REGEN-COV (casirivimab and imdevimab) to Treat COVID 19

 Regeneron Reports the EUA Expansion for REGEN-COV (casirivimab and imdevimab) to Treat COVID 19

Regeneron Reports the EUA Expansion for REGEN-COV (casirivimab and imdevimab) to Treat COVID 19

Shots:

  • The EUA is based on data from several clinical trials, including P-III trial evaluating REGEN-COV (SC injection or IV infusion) vs PBO in high-risk patients with COVID-19 for post-exposure prophylaxis. The trial is jointly run with the NIAID
  • The results showed 81% reduction in the risk of symptomatic infections while 62% reduction in asymptomatic patients based on a post-hoc analysis
  • Regeneron collaborates with Roche to increase global supply of the Ab cocktail & Roche is responsible for development and distribution outside the US. REGEN-COV is currently available in 20+ countries including U.S., EU, India, Switzerland and Canada, and is also fully approved in Japan

Click here to  to read full press release/ article | Ref: Regeneron | Image: WRGB

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post